Jason Duncan - 18 Jan 2022 Form 4 Insider Report for ALBIREO PHARMA, INC.

Role: Chief Legal Officer and GC
Signature: /s/ Jason Duncan
Issuer symbol: N/A
Transactions as of: 18 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 20 Jan 2022, 15:52:35 UTC
Previous filing: 25 Oct 2021
Next filing: 25 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALBO	Common Stock	Award	$0	+10,800	+143%	$0.000000	18,351	18 Jan 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALBO	Stock Option (right to buy)	Award	$0	+15,900		$0.000000	15,900	18 Jan 2022	Common Stock	15,900	$26.75	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026.
F2	Represents 488 shares of common stock and 17,863 restricted stock units. Includes 196 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2021.
F3	This option vests as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026.